bioXXmed AG, an investment company, invests in biotechnology or medical technology companies with equity or debt capital. It engages in the development of products for the diagnosis, alleviation, or cure of diseases through investments. The company was formerly known as CytoTools AG and changed its name to bioXXmed AG in September 2022. The company was founded in 2000 and is based in Darmstadt, Germany.
Research context
CytoTools AG appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
CytoTools AG is currently in a long term downtrend where the price is trading 9.8% below its 200 day moving average.
From a valuation standpoint, the stock is 3987.5% more expensive than other stocks from the Financial Services sector with a price to sales ratio of 1814.7.
Based on the above factors, CytoTools AG gets an overall score of 0/5.